Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Patients Who Received Compassionate-Use Leronlimab

BACKGROUND: Leronlimab, a monoclonal antibody blocker of C-C chemokine receptor type 5 originally developed to treat human immunodeficiency virus infection, was administered as an open-label compassionate-use therapeutic for coronavirus disease 2019 (COVID-19). METHODS: Twenty-three hospitalized sev...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Bryant, Fulcher, Jennifer A, Ahn, Jenny, Berro, Marlene, Goodman-Meza, David, Dhody, Kush, Sacha, Jonah B, Naeim, Arash, Yang, Otto O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Online Only Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665416/
https://www.ncbi.nlm.nih.gov/pubmed/33079180
http://dx.doi.org/10.1093/cid/ciaa1583

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665416/
https://www.ncbi.nlm.nih.gov/pubmed/33079180
http://dx.doi.org/10.1093/cid/ciaa1583

Ejemplares similares